紫杉醇脂质体、紫杉醇注射液分别联合卡铂在卵巢癌中的疗效与药物安全性对比

Comparison of efficacy and safety of paclitaxel liposome and Paclitaxel injection combined with carboplatin in ovarian cancer

目的对比卵巢癌患者分别采用紫杉醇脂质体与紫杉醇注射液联合卡铂治疗的临床疗效与药物安全性.方法选择我院2019年3月~2020年9月期间收治的60例卵巢癌患者作为本次研究的观察对象,将60例卵巢癌患者按照抽签法分为对照组与观察组,各30例,对照组给予紫杉醇注射液联合卡铂治疗,观察组给予紫杉醇脂质体联合卡铂治疗,比较两组患者治疗后的临床治疗效果及不良反应发生情况.结果两组患者治疗后临床疗效比较无明显差异(P>0.05);治疗后,观察组的不良反应发生情况明显少于对照组(P<0.05).结论紫杉醇注射液与紫杉醇脂质体两种药物治疗卵巢癌疗效相当,就安全性比较而言,紫杉醇脂质体的不良反应较少,临床应用价值较高.

Objective To compare the clinical efficacy and safety of paclitaxel liposome and Paclitaxel injection combined with carboplatin in the treatment of ovarian cancer.Methods 60 cases of ovarian cancer patients in our hospital from March 2019 to September 2020 were selected as the observation objects of this study.According to the drawing method,60 cases of ovarian cancer patients were divided into the control group and the observation group,30 cases in each group.The control group was given Paclitaxel Injection Combined with carboplatin treatment,and the observation group was given paclitaxel liposome combined with carboplatin treatment The occurrence of good reaction.Results There was no significant difference in the clinical efficacy between the two groups after treatment(P>0.05);after treatment,the incidence of adverse reactions in the observation group was significantly less than that in the control group(P<0.05).Conclusion Paclitaxel injection and paclitaxel liposome have the same curative effect in the treatment of ovarian cancer.In terms of safety,paclitaxel liposome has less adverse reactions and higher clinical application value.